SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors..

圣地亚哥--（商业新闻短讯）--Janux Therapeutics，Inc.（纳斯达克：JANX）（Janux），一家临床阶段的生物制药公司，通过将其专有技术应用于其肿瘤激活T细胞接合器（TRACTr）和肿瘤激活免疫调节剂（TRACIr）平台，开发了广泛的新型免疫疗法渠道，今天宣布任命埃里克·多梅耶和娜塔莎·赫恩代为董事会成员。。

“Eric and Natasha’s vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Janux at this pivotal stage of our growth,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “Eric’s extensive experience in biopharmaceutical operations and strategic growth will be invaluable as Janux continues to advance its pipeline.

Janux Therapeutics总裁兼首席执行官David Campbell博士说：“埃里克和娜塔莎在生物制药行业的丰富经验和公认的领导地位，是Janux在我们发展的关键阶段的巨大资产。”。“随着Janux继续推进其生产线，Eric在生物制药运营和战略增长方面的丰富经验将非常宝贵。

Natasha’s background in corporate strategy and identifying, executing and managing high-value partnerships will be essential as Janux looks to expand its opportunities to further its mission in developing next-generation cancer therapies.”.

Natasha在公司战略以及识别、执行和管理高价值合作伙伴关系方面的背景至关重要，因为Janux希望扩大其机会，进一步发展其在开发下一代癌症疗法方面的使命。”。

Dr. Campbell continued, “Their contributions will not only enhance our strategic direction but ultimately benefit patients through the potential development of next-generation cancer therapies. We are excited to welcome them to our Board and look forward to their contributions.”

坎贝尔博士继续说：“他们的贡献不仅将加强我们的战略方向，而且最终将通过下一代癌症疗法的潜在发展使患者受益。我们很高兴欢迎他们加入我们的董事会，并期待他们的贡献。”

Eric Dobmeier, J.D. has more than 20 years of experience in the biotechnology industry as both an executive and board member. Most recently, he was the President and CEO of Chinook Therapeutics, where he led the company through multiple strategic growth initiatives ultimately leading to its acquisition by Novartis in 2023 for $3.5 billion.

Eric Dobmeier，J.D.作为执行董事和董事会成员，在生物技术行业拥有20多年的经验。最近，他担任Chinook Therapeutics的总裁兼首席执行官，领导公司通过多项战略增长计划，最终于2023年以35亿美元被诺华收购。

Prior to Chinook, Mr. Dobmeier spent 16 years in a series of positions of increasing responsibility at Seattle Genetics, including Chief Operating Officer, during the company’s growth from 60 to 1,200 employees, from a market cap of $150 million to over $8 billion and through its transition to a commercial company with FDA approval and launch of Adcetris, a novel lymphoma drug.

在加入奇努克之前，多布迈耶先生在西雅图遗传学公司（Seattle Genetics）担任了16年的一系列职责日益增加的职位，包括首席运营官，该公司的员工从60人增加到1200人，市值从1.5亿美元增加到80多亿美元，并通过FDA批准向商业公司过渡，推出了一种新型淋巴瘤药物Adcetris。

During his career, Mr. Dobmeier has been directly involved in raising more than $2 billion in equity capital and led negotiation of many corporate alliances with leading biotechnology and pharmaceutical companies. He is currently a venture partner at Samsara Biocapital and serves on the boards of directors of Structure Therapeutics and Abdera Therapeutics..

在他的职业生涯中，多布迈尔先生直接参与筹集了20多亿美元的股本，并领导了与领先的生物技术和制药公司的许多企业联盟谈判。他目前是Samsara Biocapital的风险合伙人，并担任Structure Therapeutics和Abdera Therapeutics的董事会成员。。

Natasha Hernday previously served as Chief Business Officer and a member of the Executive Committee at Seagen Inc. (formerly Seattle Genetics) and was pivotal in driving business development, including alliance management, strategic partnerships, mergers, and acquisitions. Ms. Hernday led the acquisition of Cascadian Therapeutics in 2018 for approximately $614 million and a global strategic oncology collaboration with Merck in 2020 for over $1.5 billion in upfront cash and equity.

Natasha Hernday曾担任Seagen Inc.（前西雅图遗传学）的首席商务官和执行委员会成员，在推动业务发展方面发挥了关键作用，包括联盟管理、战略合作伙伴关系、合并和收购。。

Cascadian’s lead asset has since been approved and is achieving over $400 million in yearly revenue. Ms. Hernday’s strategic insight and successful track record in transactions culminated in Seagen's acquisition by Pfizer in 2023 for $43 billion. Prior to her role at Seagen, Ms. Hernday spent 16 years at Amgen, where she began her career in discovery research, then held various leadership positions in corporate development and corporate strategy, including as Director, Mergers & Acquisitions and as Director, Out-Partnering, playing a key role in numerous high-value transactions.

卡斯卡迪亚的领先资产已获得批准，年收入超过4亿美元。Hernday女士的战略洞察力和成功的交易记录最终导致希根于2023年以430亿美元被辉瑞收购。在担任Seagen之前，Hernday女士在安进（Amgen）工作了16年，在安进（Amgen）开始了她的发现研究职业生涯，然后在公司发展和公司战略方面担任了各种领导职位，包括并购主管和外部合作主管，在众多高价值交易中发挥了关键作用。

Additionally, Ms. Hernday served on the Board of Alpine Immune Sciences, which was acquired by Vertex Pharmaceuticals in 2024 for $4.9 billion..

此外，Hernday女士还在Alpine Immune Sciences董事会任职，该董事会于2024年被Vertex Pharmaceuticals以49亿美元收购。。

In addition, Janux announced the resignation of Jay Lichter, Ph.D., from the Board of Directors. Dr. Lichter, a key figure as the head of Janux’s founding seed investor Avalon Ventures, has been instrumental in the company’s growth and success. Current Board member Ronald W. Barrett, Ph.D., will replace Jay Lichter as Chairperson of the Board..

此外，Janux宣布Jay Lichter博士从董事会辞职。利希特博士是Janux创始种子投资者阿瓦隆风险投资公司（AvalonVentures）的负责人，是该公司成长和成功的关键人物。现任董事会成员Ronald W.Barrett博士将接替Jay Lichter担任董事会主席。。

“We deeply appreciate Jay’s leadership and dedication over the years,” said Dr. Campbell. “His vision and commitment have been integral to our achievements, and for that, we thank him deeply. Ron’s extensive experience and leadership in the biopharmaceutical industry will be vital as Janux continues to advance its innovative pipeline, and I look forward to his continued stewardship and contributions.”.

坎贝尔博士说：“我们非常感谢杰伊多年来的领导和奉献精神。”。“他的远见和承诺是我们取得成就不可或缺的一部分，为此，我们深表感谢。随着Janux继续推进其创新渠道，Ron在生物制药行业的丰富经验和领导力将至关重要，我期待着他继续领导和贡献。”。

Janux’s TRACTr and TRACIr Pipeline

Janux的Tracr和TRACIr管道

Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). Janux’s second clinical candidate, JANX008, is a TRACTr that targets EGFR and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Janux的第一个临床候选者JANX007是一种针对PSMA的TRACTr，目前正在对患有转移性去势抵抗性前列腺癌（mCRPC）的成年受试者进行1期临床试验。Janux的第二个临床候选者JANX008是一种靶向EGFR的TRACTr，正在进行一期临床试验，用于治疗多种实体癌，包括结直肠癌，头颈部鳞状细胞癌，非小细胞肺癌和肾细胞癌。

We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline..

。我们目前正在评估临床前流程中的优先事项。。

About Janux Therapeutics

关于Janux Therapeutics

Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns.

Janux是一家临床阶段的生物制药公司，开发针对癌症的肿瘤激活免疫疗法。Janux的专有技术能够开发两种不同的双特异性平台：肿瘤激活的T细胞接受者（TRACTr）和肿瘤激活的免疫调节剂（TRACIr）。这两个平台的目标是为癌症患者提供安全有效的治疗方法，指导他们的免疫系统根除肿瘤，同时最大程度地减少安全问题。

Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal, lung, head and neck, and renal cancers.

Janux目前正在开发针对几种治疗实体瘤的靶点的广泛TRACTr和TRACIr治疗药物。Janux在临床试验中有两种TRACTr治疗候选药物，第一种靶向PSMA正在开发用于前列腺癌，第二种靶向EGFR正在开发用于结直肠癌，肺癌，头颈癌和肾癌。

For more information, please visit www.januxrx.com and follow us on LinkedIn..

有关更多信息，请访问www.januxrx.com并在LinkedIn上关注我们。。

Forward-Looking Statements

前瞻性声明

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux’s development activities, including its ongoing and planned preclinical studies and clinical trials, the potential benefits of Janux’s product candidates and platform technologies and expectations regarding the use of Janux’s platform technologies to generate novel product candidates.

本新闻稿包含某些涉及风险和不确定性的前瞻性陈述，这些风险和不确定性可能导致实际结果与历史结果或此类前瞻性陈述所表达或暗示的任何未来结果存在重大差异。此类前瞻性陈述包括以下方面的陈述：Janux为有需要的癌症患者带来新疗法的能力，对Janux开发活动的时间，范围和结果的期望，包括其正在进行和计划中的临床前研究和临床试验，Janux候选产品和平台技术的潜在益处，以及对使用Janux平台技术产生新候选产品的期望。

Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

可能导致实际结果产生重大差异的因素包括：在早期研究中看起来有希望的化合物在后来的临床前研究或临床试验中没有显示出安全性和/或有效性的风险，Janux可能无法获得批准以销售其候选产品的风险，与进行临床试验，监管备案和应用相关的不确定性，与依赖第三方成功进行临床试验相关的风险，与依赖外部融资以满足资本要求相关的风险，以及与发现，开发和商业化安全有效的药物作为人类治疗药物的过程相关的其他风险，以及围绕这些药物建立业务的努力。

You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or th.

强烈建议您考虑包含“可能”、“将”、“将”、“可能”、“应该”、“相信”、“估计”、“项目”、“承诺”、“潜力”、“期望”、“计划”、“预期”、“打算”、“继续”、“设计”、“目标”或th等字样的陈述。